Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-04-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
监事会议事规则（2024年4月）
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for Harbin Yuheng Pharmaceutical Co., Ltd. It details the rules and procedures for the supervisory board meetings, including composition, powers, meeting convocations, voting procedures, record keeping, and amendments to the rules. There is no financial data, no report of financial results, no announcement of voting results, no management or board changes, no legal proceedings, no capital updates, no earnings information, and no investor presentation. The document is a governance-related internal rules document for the supervisory board, which fits the definition of Governance Information (CGR). The document length is 5694 characters, which is sufficient for a detailed governance document. Therefore, the classification is Governance Information (CGR) with high confidence.
2024-04-19 Chinese
关于2023年度不进行利润分配的专项说明公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the company's 2023 profit distribution plan, specifically stating that no dividends will be distributed for the year 2023. It includes details about the board and supervisory committee's approval of the plan, reasons for no profit distribution, and references to relevant regulations and company bylaws. The document is relatively short (1335 characters) and serves as an official announcement of the profit distribution decision rather than a full financial report or detailed earnings release. It does not contain comprehensive financial statements or detailed analysis but rather the outcome of a board decision and related disclosures. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend decision (no dividend) for the fiscal year 2023.
2024-04-19 Chinese
2023年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed summary table of non-operating fund occupation and other related party fund transactions for the year 2023 by Harbin Yuheng Pharmaceutical Co., Ltd. It includes financial figures such as balances, cumulative amounts, and interest related to these transactions. The document is 1851 characters long, which is relatively short and does not contain comprehensive financial statements or analysis typical of an Interim/Quarterly Report or Annual Report. It is not an announcement of a report publication but a specific financial disclosure related to related party transactions and fund usage. This type of detailed financial disclosure about related party transactions and non-operating fund occupation is typically part of regulatory compliance filings or disclosures but does not fit the definitions of other categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length, and that it is a specific financial disclosure document, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not neatly fit into other categories.
2024-04-19 Chinese
公司章程（2024年4月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for Harbin Gloria Pharmaceuticals Co., Ltd., including comprehensive sections on company organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. It is a legal and governance document outlining the company's internal rules and procedures rather than a financial report, announcement, or meeting material. There is no indication of financial statements, audit reports, earnings data, or meeting results. The content aligns with governance information about the company's internal rules and board structure. Therefore, the document best fits the category of Governance Information (CGR).
2024-04-19 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the external audit firm for the fiscal year 2023. It details the audit firm's qualifications, independence, audit scope, and communication with the company, as well as the committee's oversight activities. The document does not contain the audit report itself or detailed financial statements but rather an assessment and supervisory report on the audit firm's work. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations related to audit firms and their work, excluding full annual reports. The document length is 2773 characters, which is consistent with a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2023
2024-04-19 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report". It is issued by a certified public accounting firm and addresses the internal control over financial reporting for the fiscal year ending December 31, 2023. The content includes detailed descriptions of the company's internal control responsibilities, the auditor's responsibilities, the scope of the internal control audit, evaluation criteria for control deficiencies, and conclusions on the effectiveness of internal controls. It also includes an internal control self-evaluation report by the company. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other types of filings. It matches the definition of an Audit Report / Information (AR) as it is a standalone audit report on internal controls, excluding a full annual report. The document length (10,473 characters) is sufficient to be the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.